The global theranostics market Size
is anticipated to reach over USD 20.52 Billion by 2026 according to a new
study published by Polaris Market Research.
Theranostics are defined as a
combination of diagnostics and drug therapeutics to improve the drug safety,
drug restructures development and effectiveness. The combination of effective
medical drugs and advanced diagnostic tests has been given numerous names, such
as Dx/Rx partnering, integrated medicine, pharmacodiagnostics, and companion
diagnostics.
Get Sample PDF @ https://www.polarismarketresearch.com/industry-analysis/global-theranostics-market/request-for-sample
The increasing occurrence of
life-threatening and chronic diseases and the demand for innovative
chemotherapeutic treatments associated with the need for improving disease detection
are the key factors propelling the global theranostics market. In addition, the
rising potential of clinically adaptable nanomaterials in the biological
imaging area and therapy is expected to bolster the market growth. Moreover,
improved collaboration between drug and diagnostics firms are anticipated to
enhance the growth of the theranostics market. In addition, a decrease in costs
and reduced time required for medical trials monitored by pharmaceutical
segments are another key drivers propelling the growth of the global
theranostics market.
The global theranostics market is
segmented on the basis of disease type, technology, and geography. On the basis
of disease type, the global theranostics market is segmented into Neurological
Disorders, Cardiovascular Diseases, Oncology Disorders, and Immunological
Disorders. On the basis of disease type, the oncology segment is anticipated to
boost the market growth. Increasing cancer cases and theranostics potentials to
make effective cancer care are the factors associated with the market growth.
Get Special Discount On this Research Report @ https://www.polarismarketresearch.com/industry-analysis/global-theranostics-market/request-for-discount-pricing
On the basis of technology, the
global theranostics market is segmented into Polymerase Chain Reaction (PCR),
In-situ Hybridization, Immunohistochemistry, and sequencing. In 2017, the PCR
is anticipated to dominate the market growth. The existence of a robust
evaluate assortment in terms of polymerase chain reaction (PCR) is accountable
for the larger market share.
Some major key players in global
theranostics market include F Hoffman La Roche, Thermo Fisher Scientific Inc.,
GE Healthcare, Agilent Technologies, Qiagen NV, Foundation Medicine, Leica
Biosystems Nussloch GmBH, and Pfizer, Inc. among others.
Contact us-
Polaris Market Research
Phone: 1-646-568-9980
No comments:
Post a Comment
Please do not enter any spam link in the comment box...